logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11566230 B1

PDFFull Text
Date of Patent:
Jan. 31, 2023

Filed:

Dec. 31, 2021

Universal donor cells

Applicant:

Crispr Therapeutics Ag, Zug, CH;

Inventors:

Alireza Rezania, Cambridge, MA (US);

Valentin Sluch, Cambridge, MA (US);

Assignee:

CRISPR THERAPEUTICS AG, Zug, CH;

Attorney:

Sheppard, Mullin, Richter & Hampton LLP

Primary Examiner:

Jennifer Dunston

Int. Cl.
CPC ...
C12N 15/85 (2006.01); C12N 15/90 (2006.01); C12N 9/22 (2006.01); C07K 14/74 (2006.01); A61K 35/545 (2015.01); C12N 5/0735 (2010.01); C12N 5/074 (2010.01); C12N 5/071 (2010.01); A61P 1/18 (2006.01); A61K 35/39 (2015.01); C07K 14/475 (2006.01); C07K 14/525 (2006.01); C07K 14/705 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0676 (2013.01); A61K 35/39 (2013.01); A61K 35/545 (2013.01); A61P 1/18 (2018.01); C07K 14/475 (2013.01); C07K 14/525 (2013.01); C07K 14/70532 (2013.01); C07K 14/70539 (2013.01); C12N 5/0606 (2013.01); C12N 5/0696 (2013.01); C12N 9/22 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); A61K 38/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/035 (2013.01); C07K 2319/09 (2013.01); C12N 2506/02 (2013.01); C12N 2506/03 (2013.01); C12N 2506/45 (2013.01); C12N 2510/00 (2013.01);
Abstract

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor.

Find Patent Forward Citations

Loading…